Screener / SEC EDGAR /CIK 0001699031 /10-K filed Mar 12, 2026, compared with Mar 5, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

GRAIL, Inc. GRAL

Compare with peers Embed

GRAL among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+17.2%48th of 155 · median +10.5%
Net margin
-4.1%15.3%
-243.8%147th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-16.6%115th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-187.3%137th of 145 · median 10.0%

GRAL and 9 peers, year by year

The 9 Health care companies closest to GRAL in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
GRAL GRAIL, Inc. FY2025 $147.2M+17.2%-−382.0%−277.5%−203.8%−15.8%-
BEAM Beam Therapeutics Inc. FY2025 $139.7M+120%-−274.6%−57.2%−257.7%−6.5%-
AGIO Agios Pharmaceuticals, Inc. FY2025 $54.0M+48.0%-−873.9%−764.0%−698.3%−34.6%-
RVMD Revolution Medicines, Inc. FY2025 $0-----−69.3%-
CYTK Cytokinetics Inc FY2025 $88.0M+377%-−695.4%−891.6%−607.5%n/mn/m
KYMR Kymera Therapeutics, Inc. FY2025 $39.2M−16.7%-−891.1%−794.0%−597.6%−19.7%-
LGND Ligand Pharmaceuticals Inc FY2025 $268.1M+60.4%-15.3%46.4%18.2%12.2%-
RXRX Recursion Pharmaceuticals, Inc. FY2025 $74.7M+26.9%-−867.9%−863.4%−506.5%−57.0%0.02
LMAT Lemaitre Vascular Inc FY2025 $249.6M+13.5%71.5%27.2%23.1%29.8%14.7%-
RYTM Rhythm Pharmaceuticals, Inc. FY2025 $189.8M+45.8%-−101.2%−103.6%−61.5%−141.3%0.78

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2022 to FY2025 · 10-K XBRL

GRALGRAIL, Inc.
FY2022 revenue $55.5MFY2023 revenue $93.1MFY2024 revenue $125.6MFY2025 revenue $147.2M FY2025 net margin −277.5% FY2022FY2025
Revenue$147.2M Growth+17.2% Net margin−277.5%
BEAMBeam Therapeutics Inc.
FY2022 revenue $60.9MFY2023 revenue $377.7MFY2024 revenue $63.5MFY2025 revenue $139.7M FY2022 net margin −474.5%FY2023 net margin −35.1%FY2024 net margin −593.1%FY2025 net margin −57.2% FY2022FY2025
Revenue$139.7M Growth+120% Net margin−57.2%
AGIOAgios Pharmaceuticals, Inc.
FY2022 revenue $14.2MFY2023 revenue $26.8MFY2024 revenue $36.5MFY2025 revenue $54.0M FY2025 net margin −764.0% FY2022FY2025
Revenue$54.0M Growth+48.0% Net margin−764.0%
RVMDRevolution Medicines, Inc.
FY2022 revenue $35.4MFY2023 revenue $11.6M FY2022 net margin −703.0% FY2022FY2025
Revenue$0 Growth−100% Net margin−703.0%
CYTKCytokinetics Inc
FY2022 revenue $94.6MFY2023 revenue $7.5MFY2024 revenue $18.5MFY2025 revenue $88.0M FY2022 net margin −411.2%FY2025 net margin −891.6% FY2022FY2025
Revenue$88.0M Growth+377% Net margin−891.6%
KYMRKymera Therapeutics, Inc.
FY2022 revenue $46.8MFY2023 revenue $78.6MFY2024 revenue $47.1MFY2025 revenue $39.2M FY2022 net margin −330.6%FY2023 net margin −187.0%FY2024 net margin −475.6%FY2025 net margin −794.0% FY2022FY2025
Revenue$39.2M Growth−16.7% Net margin−794.0%
LGNDLigand Pharmaceuticals Inc
FY2022 revenue $196.2MFY2023 revenue $131.3MFY2024 revenue $167.1MFY2025 revenue $268.1M FY2022 net margin −17.0%FY2023 net margin 39.7%FY2024 net margin −2.4%FY2025 net margin 46.4% FY2022FY2025
Revenue$268.1M Growth+60.4% Net margin46.4%
RXRXRecursion Pharmaceuticals, Inc.
FY2022 revenue $39.8MFY2023 revenue $44.6MFY2024 revenue $58.8MFY2025 revenue $74.7M FY2022 net margin −601.0%FY2023 net margin −736.0%FY2024 net margin −788.0%FY2025 net margin −863.4% FY2022FY2025
Revenue$74.7M Growth+26.9% Net margin−863.4%
LMATLemaitre Vascular Inc
FY2022 revenue $161.7MFY2023 revenue $193.5MFY2024 revenue $219.9MFY2025 revenue $249.6M FY2022 net margin 12.8%FY2023 net margin 15.6%FY2024 net margin 20.0%FY2025 net margin 23.1% FY2022FY2025
Revenue$249.6M Growth+13.5% Net margin23.1%
RYTMRhythm Pharmaceuticals, Inc.
FY2022 revenue $23.6MFY2023 revenue $77.4MFY2024 revenue $130.1MFY2025 revenue $189.8M FY2022 net margin −766.2%FY2023 net margin −238.5%FY2024 net margin −200.3%FY2025 net margin −103.6% FY2022FY2025
Revenue$189.8M Growth+45.8% Net margin−103.6%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2022 to FY2025

Revenue as reported in the 10-K.

$0 $377.7M FY2022FY2023FY2024FY2025 BEAM: $60.9M, $377.7M, $63.5M, $139.7M BEAM AGIO: $14.2M, $26.8M, $36.5M, $54.0M AGIO RVMD: $35.4M, $11.6M, $0, $0 RVMD CYTK: $94.6M, $7.5M, $18.5M, $88.0M CYTK KYMR: $46.8M, $78.6M, $47.1M, $39.2M KYMR LGND: $196.2M, $131.3M, $167.1M, $268.1M LGND RXRX: $39.8M, $44.6M, $58.8M, $74.7M RXRX LMAT: $161.7M, $193.5M, $219.9M, $249.6M LMAT RYTM: $23.6M, $77.4M, $130.1M, $189.8M RYTM GRAL: $55.5M, $93.1M, $125.6M, $147.2M GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $377.7M. A gap is a year with no number.

Sales growth, FY2022 to FY2025

Revenue against the fiscal year before.

−100% +649% FY2022FY2023FY2024FY2025 BEAM: +17.5%, +520%, −83.2%, +120% BEAM AGIO: -, +88.4%, +36.1%, +48.0% AGIO RVMD: +20.4%, −67.3%, −100%, - RVMD CYTK: +34.3%, −92.0%, +145%, +377% CYTK KYMR: −35.7%, +67.8%, −40.1%, −16.7% KYMR LGND: −18.8%, −33.1%, +27.3%, +60.4% LGND RXRX: +291%, +11.9%, +32.0%, +26.9% RXRX LMAT: +4.7%, +19.7%, +13.6%, +13.5% LMAT RYTM: +649%, +228%, +68.1%, +45.8% RYTM GRAL: -, +67.6%, +34.9%, +17.2% GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −100% to +649%. A gap is a year with no number. A ring marks where a line starts: GRAL, AGIO have no earlier 10-K here.

Gross margin, FY2022 to FY2025

Gross profit / revenue.

64.9% 71.5% FY2022FY2023FY2024FY2025 LMAT: 64.9%, 65.7%, 68.6%, 71.5% LMAT
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 64.9% to 71.5%. A gap is a year with no number.
CompanyFY2022FY2023FY2024FY2025
GRAL Dec ----
BEAM Dec ----
AGIO Dec ----
RVMD Dec ----
CYTK Dec ----
KYMR Dec ----
LGND Dec ----
RXRX Dec ----
LMAT Dec 64.9%65.7%68.6%71.5%
RYTM Dec ----
Peer median----

Operating margin, FY2022 to FY2025

Operating income / revenue.

−891.1% 27.2% FY2022FY2023FY2024FY2025 BEAM: −555.6%, −46.7%, −654.3%, −274.6% BEAM AGIO: n/m, n/m, n/m, −873.9% AGIO RVMD: −730.0%, n/m, -, - RVMD CYTK: −342.8%, n/m, n/m, −695.4% CYTK KYMR: −344.4%, −210.6%, −555.8%, −891.1% KYMR LGND: 1.5%, 9.1%, −13.5%, 15.3% LGND RXRX: −616.7%, −785.3%, −814.1%, −867.9% RXRX LMAT: 16.6%, 19.0%, 23.8%, 27.2% LMAT RYTM: −757.9%, −238.1%, −204.0%, −101.2% RYTM GRAL: n/m, n/m, n/m, −382.0% GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −891.1% to 27.2%. A gap is a year with no number. A ring marks where a line starts: GRAL, AGIO have no earlier 10-K here.

Net margin, FY2022 to FY2025

Net income / revenue.

−891.6% 46.4% FY2022FY2023FY2024FY2025 BEAM: −474.5%, −35.1%, −593.1%, −57.2% BEAM AGIO: n/m, n/m, n/m, −764.0% AGIO RVMD: −703.0%, n/m, -, - RVMD CYTK: −411.2%, n/m, n/m, −891.6% CYTK KYMR: −330.6%, −187.0%, −475.6%, −794.0% KYMR LGND: −17.0%, 39.7%, −2.4%, 46.4% LGND RXRX: −601.0%, −736.0%, −788.0%, −863.4% RXRX LMAT: 12.8%, 15.6%, 20.0%, 23.1% LMAT RYTM: −766.2%, −238.5%, −200.3%, −103.6% RYTM GRAL: n/m, n/m, n/m, −277.5% GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −891.6% to 46.4%. A gap is a year with no number. A ring marks where a line starts: GRAL, AGIO have no earlier 10-K here.

Free cash flow, FY2022 to FY2025

Cash from operations minus capital spending.

−$913.7M $119.9M FY2022FY2023FY2024FY2025 BEAM: −$26.4M, −$182.9M, −$356.2M, −$360.0M BEAM AGIO: −$314.4M, −$297.1M, −$391.5M, −$377.3M AGIO RVMD: −$235.2M, −$358.3M, −$567.7M, −$913.7M RVMD CYTK: −$310.9M, −$415.7M, −$399.8M, −$534.8M CYTK KYMR: −$155.9M, −$137.3M, −$207.3M, −$234.3M KYMR LGND: $119.9M, $46.1M, $95.2M, $48.9M LGND RXRX: −$120.6M, −$299.7M, −$372.9M, −$378.3M RXRX LMAT: $22.1M, $29.5M, $37.2M, $74.5M LMAT RYTM: −$173.7M, −$136.2M, −$113.9M, −$116.6M RYTM GRAL: −$584.2M, −$608.7M, −$582.4M, −$299.9M GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$913.7M to $119.9M. A gap is a year with no number.

FCF margin, FY2022 to FY2025

Free cash flow / revenue.

−734.9% 61.1% FY2022FY2023FY2024FY2025 BEAM: −43.4%, −48.4%, −560.8%, −257.7% BEAM AGIO: n/m, n/m, n/m, −698.3% AGIO RVMD: −664.8%, n/m, -, - RVMD CYTK: −328.6%, n/m, n/m, −607.5% CYTK KYMR: −333.0%, −174.7%, −440.5%, −597.6% KYMR LGND: 61.1%, 35.1%, 57.0%, 18.2% LGND RXRX: −302.6%, −672.4%, −633.7%, −506.5% RXRX LMAT: 13.7%, 15.2%, 16.9%, 29.8% LMAT RYTM: −734.9%, −175.9%, −87.5%, −61.5% RYTM GRAL: n/m, −653.8%, −463.7%, −203.8% GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −734.9% to 61.1%. A gap is a year with no number. A ring marks where a line starts: GRAL, AGIO have no earlier 10-K here.

Return on equity, FY2022 to FY2025

Net income / shareholders' equity at the year end.

−141.3% 43.7% FY2022FY2023FY2024FY2025 BEAM: −39.4%, −13.5%, −51.4%, −6.5% BEAM AGIO: −21.1%, −43.4%, 43.7%, −34.6% AGIO RVMD: −36.3%, −23.9%, −26.5%, −69.3% RVMD KYMR: −31.6%, −37.2%, −26.8%, −19.7% KYMR LGND: −5.6%, 7.4%, −0.5%, 12.2% LGND RXRX: −49.3%, −70.8%, −44.8%, −57.0% RXRX LMAT: 7.7%, 10.1%, 13.1%, 14.7% LMAT RYTM: −68.5%, −108.8%, n/m, −141.3% RYTM GRAL: -, -, −81.0%, −15.8% GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −141.3% to 43.7%. A gap is a year with no number. A ring marks where a line starts: GRAL has no earlier 10-K here.

Debt / equity, FY2022 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.05 FY2022FY2023FY2024FY2025 RXRX: 0.00, 0.00, 0.03, 0.02 RXRX RYTM: -, 0.63, 5.05, 0.78 RYTM
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.05. A gap is a year with no number. A ring marks where a line starts: RYTM has no earlier 10-K here.
CompanyFY2022FY2023FY2024FY2025
GRAL Dec ----
BEAM Dec ----
AGIO Dec ----
RVMD Dec ----
CYTK Dec n/mn/mn/mn/m
KYMR Dec ----
LGND Dec ----
RXRX Dec 0.000.000.030.02
LMAT Dec ----
RYTM Dec -0.635.050.78
Peer median----

EPS (diluted), FY2022 to FY2025

Diluted earnings per share, on today's share count after splits.

−$173.89 $11.64 FY2022FY2023FY2024FY2025 BEAM: −$4.13, −$1.72, −$4.58, −$0.81 BEAM AGIO: −$4.23, −$6.33, $11.64, −$7.12 AGIO RVMD: −$3.08, −$3.86, −$3.58, −$5.95 RVMD CYTK: −$4.33, −$5.45, −$5.26, −$6.54 CYTK KYMR: −$2.87, −$2.52, −$2.98, −$3.69 KYMR LGND: −$1.98, $2.94, −$0.22, $6.13 LGND RXRX: −$1.36, −$1.58, −$1.69, −$1.44 RXRX LMAT: $0.93, $1.34, $1.93, $2.52 LMAT RYTM: −$3.47, −$3.20, −$4.34, −$3.11 RYTM GRAL: −$173.89, −$47.21, −$63.54, −$11.11 GRAL
GRAL is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$173.89 to $11.64. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out GRAL and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: GRAL's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.